The stock has lost about 25% of its value in 2016, and management has taken advantage of the plunge by repurchasing about 100 million shares of its own stock. While it’s nice to know the shares were purchased at knockdown prices, it’s hard to remain cheerful when your stock price is sinking.
Category: Healthcare Industry
ContraVir expands mid-stage study of tenofovir prodrug analog into higher dose
ContraVir Pharmaceuticals broadens its ongoing Phase 2a study evaluating tenofovir exalidex against Gilead Sciences’ tenofovir disoproxil fumarate in patients with chronic hepatitis B virus infection by increasing the highest planned dose to 150 mg/day from 100 mg/day. The 84-subject sequential dose escalation study is assessing once-daily doses of TXL for four weeks against 300 mg of TDF once daily.
Therapy Focus – Immunotherapy Closes In On Triple-Negative Tumors
Celgene admitted as much last week by saying it would not push a promising Abraxane-containing chemotherapy regimen into pivotal trials in this Several studies are already under way, most notably a large first-line phase III trial of Abraxane plus Roche’s anti-PD-L1 antibody Tecentriq. Early data are encouraging, and hopes are high that meaningful survival benefits will emerge in the next couple of years.
DPP IV Inhibitors
… Global Diabetes Expenditure: Opportunity Indicator for DPP-IV Inhibitor Market………….. II-5 Table 3: Global Health Expenditure on Diabetes by Region (2015): Spending (in US$ Billion) by People Diagnosed with Diabetes in the Age Group 20-79 …
Press release distribution, EDGAR filing, XBRL, regulatory filings
Pfizer Receives Approval in the European Union for Nimenrix in Infants Six Weeks of Age and Older )–Pfizer Inc. announced today the European Commission has approved an expanded indication for Nimenrixa Approved as First Anti-PD-1 Therapy in Japan for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Express High Levels of PD-L1 )–KEYTRUDA Approved as First Anti-PD-1 Therapy in Japan for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Express H… )–Madame Tussauds and country superstar Brad Paisley joined forces to pay tribute to Grand Ole Opry legend Little Jimmy Dickens by unveiling his wax figure on the R… )–Manitowoc Foodservice announces SVP, General Counsel and Secretary Maurice Jones retirement; promotes Joel Horn to SVP, General Counsel and Secretary effecti… )–Mitsubishi UFJ Capital, a … (more)
GSK starts phase III study of once-daily closed triple combination…
… endpoint is the annualised rate of moderate/severe asthma exacerbations. Other secondary endpoints are assessing health-related quality of life and symptom control. Despite the availability of treatments, many patients have asthma that is …
SK Chemicals’ hemophilia drug approved in Canada
SK Chemicals, the biopharmaceuticals unit of South Korea’s SK Group, has obtained regulatory approval to sell its hemophilia treatment in Canada, marking another step forward in breaking into overseas markets. SK Chemicals said Sunday that Health Canada, the country’s drug regulator, has granted marketing and sales approval for Afstyla, a biologic drug for hemophilia developed by SK Chemicals and licensed out to Australian biotech firm CSL Ltd. in 2009.
View Press Release
A Once-Daily Treatment that Demonstrated Comparable Efficacy with Improved Renal and Bone Laboratory Safety Parameters Compared to Tenofovir Disoproxil Fumarate — )–Gilead Sciences, Inc. today announced that the Japanese Ministry of Health, Labour and Welfare has approved Vemlidy 25mg, a once-daily treatment for suppression of viral replication in chronic hepatitis B patients with evidence of hepatitis B virus replication and abnormal liver function. Vemlidy is a novel targeted prodrug of tenofovir that has demonstrated antiviral efficacy similar to and at a dose less than one-tenth that of tenofovir disoproxil fumarate 300mg.
Overindulging at Christmas is one cause of the spike in heart attacks over the holidays.
… Mehta notes. These factors include logistical (inappropriate delay in seeking medical attention, reduced levels of health care staffing) and environmental (increased respiratory problems, decreased hours of daylight), as well as lifestyle ones – …
Johnson & Johnson Completes Acquisition of Abbott Medical Optics
The all-cash , and includes ophthalmic products in three areas of patient care: cataract surgery, laser refractive surgery and consumer eye health. These product lines will now join with the world-leading ACUVUEA Brand Contact Lenses business, and the combined organization will operate under the brand name Johnson & Johnson Vision .
FDA warns Pfizer over contaminated drugs at Kansas plant
… that your company’s oversight and control over the manufacturer of drugs is inadequate,” the FDA said. – Most people aren’t aware that surgeons are sometimes involved in multiple operations happening at the same time, and many …